Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor
	Acts as a drug target< (This gene does not contain this module)

Gene: JUNB

Summary for JUNB

Gene information	Gene symbol	JUNB
	Ensembl ID	ENSG00000171223
	Entrez ID	3726
	Gene name	JunB proto-oncogene, AP-1 transcription factor subunit
	Synonyms	NA
	Gene type	protein_coding
	UniProtAcc	P17275

Top

Dataset with differentially expressed gene: JUNB

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	-1.1085	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.802456	1.13e-26
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.619235	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.601485	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	0.585849	2.90e-15
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.355831	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.286103	2.37e-43
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.407664	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.555321	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.979116	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.744449	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.2835	1.69e-27
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.328898	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	1.06694	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.323152	1.19e-22
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.611926	3.36e-17
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.263089	3.88e-09
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.414018	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.80821	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.587223	9.83e-12
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.335846	1.31e-11
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	1.01914	4.28e-35
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.471045	8.20e-18
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mast cells	-1.15386	2.34e-04
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	-0.306329	1.45e-23
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	cDCs	0.674043	3.54e-09
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.278837	1.19e-04
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-2.33503	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-2.35044	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	0.40618	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	pre	CD4+ T cells	0.509807	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	post	CD8+ T cells	-0.426773	1.95e-42
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	-0.585341	2.82e-28
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.565189	1.36e-36
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mast cells	1.15019	1.14e-02
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.662618	4.08e-06
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	NK cells	-0.437112	6.05e-27
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	Mono/Macro	-0.250439	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.377181	2.30e-03
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.650188	4.20e-19
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	pDCs	1.38534	3.36e-03
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Malignant cells	0.668161	5.55e-22
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	0.889548	9.34e-26
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	0.449891	1.18e-02
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.540642	4.62e-26
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	1.03112	5.29e-07
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	NK cells	-0.424044	8.38e-36
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.905235	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	CD8+ T cells	-0.476386	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	1.91254	2.57e-33
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	cDCs	1.04741	1.21e-05
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD4+ T cells	0.685239	1.70e-03
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	1.00688	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-1.13272	1.16e-38
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	-0.487401	1.12e-38
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	-0.570669	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD4+ T cells	0.629493	7.58e-03
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.305112	7.83e-32
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-0.498551	4.06e-20
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	-0.366164	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.802721	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	cDCs	-0.912765	5.24e-03
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	CD4+ T cells	-0.302645	6.87e-05
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.389085	2.17e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.434564	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.265774	1.13e-26
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.744083	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	1.17885	2.25e-30
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	1.20187	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	1.66049	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	Malignant cells	-0.277725	5.64e-04
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	-0.589847	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.322682	3.43e-02
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	Malignant cells	0.463423	0.00e+00
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	CD8+ T cells	1.189	1.40e-20
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.375233	1.43e-10
GSE104987	MCF7 cell line	Cell line	Breast cancer	ER+ breast cancer	Targeted therapy	KDM5-C70	NA	Malignant cells	0.301134	3.59e-13
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	0.500435	1.68e-25
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.362273	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	0.813385	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	0.401201	1.62e-36
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-0.40425	1.74e-19
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	0.402355	2.95e-10
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	1.17415	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	1.20807	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-0.737608	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-0.592142	0.00e+00

Top

Expression of JUNB in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to JUNB

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating JUNB

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
JUNB	hsa-miR-6074	96.9176	NM_002229
JUNB	hsa-miR-376a-5p	92.9882	NM_002229
JUNB	hsa-miR-656-3p	92.8324	NM_002229
JUNB	hsa-miR-3121-3p	92.2238	NM_002229
JUNB	hsa-miR-4719	91.6061	NM_002229
JUNB	hsa-miR-4530	89.3582	NM_002229
JUNB	hsa-miR-95-5p	88.5709	NM_002229
JUNB	hsa-miR-4533	85.7144	NM_002229
JUNB	hsa-miR-3202	85.1772	NM_002229
JUNB	hsa-miR-6885-5p	83.9101	NM_002229
JUNB	hsa-miR-8485	82.4397	NM_002229
JUNB	hsa-miR-6887-3p	82.0803	NM_002229

Page: 1

Top

Motifs and transcription factors (TFs) regulating JUNB

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
JUNB	metacluster_130.15	ARID5B; ARID5B; BPTF (directAnnotation).
JUNB	transfac_pro__M08187	ABL1 (directAnnotation).
JUNB	swissregulon__hs__FUBP1	FUBP1 (directAnnotation).
JUNB	swissregulon__hs__FOXD3	FOXD3 (directAnnotation).
JUNB	metacluster_8.1	ZNF382 (directAnnotation).
JUNB	hocomoco__FOXP1_HUMAN.H11MO.0.A	FOXP1 (directAnnotation).
JUNB	transfac_public__M00278	GATA1; LDB1; LMO2; TAL1; TCF3 (inferredBy_Orthology).
JUNB	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_meth	ZNF385D (directAnnotation).
JUNB	transfac_pro__M05628	ZNF735 (directAnnotation).
JUNB	kznf__PRDM1_modENCODE.2_ChIP-seq	PRDM1 (directAnnotation).
JUNB	kznf__ZNF282_Imbeault2017_OM_RCADE	ZNF282 (directAnnotation).
JUNB	jaspar__MA1125.1	ZNF384 (directAnnotation).
JUNB	hocomoco__SOX9_HUMAN.H11MO.1.B	SOX9 (directAnnotation).
JUNB	taipale_cyt_meth__CREB1_NRTGACGTN_eDBD_repr	CREB1 (directAnnotation).
JUNB	kznf__ZNF613_Imbeault2017_RP_RCADE	ZNF613 (directAnnotation).
JUNB	kznf__CTCF_Rhee2011.2_ChIP-exo	CTCF (directAnnotation).
JUNB	kznf__ZNF384_Schmitges2016_RCADE	ZNF384 (directAnnotation).
JUNB	metacluster_168.16	FOXG1 (inferredBy_Orthology).
JUNB	transfac_public__M00266	FOXC2 (inferredBy_Orthology).
JUNB	metacluster_111.5	E4F1; E4F1 (directAnnotation).
JUNB	metacluster_188.6	DLX6; FOXA1; FOXA1; FOXA2; FOXA2; FOXA3; FOXA3; FOXC1; FOXC1; FOXC2; FOXC2; FOXC2; FOXC2; FOXD2; FOXD3; FOXD3; FOXE1; FOXE1; FOXE1; FOXJ2; FOXJ2; FOXK1; FOXL1; FOXL1; FOXM1; FOXP1; FOXP1; HMG20B; IKZF5; SKI (directAnnotation). FOXD2; FOXF1; FOXJ3; FOXK1; FOXL1; FOXL1 (inferredBy_Orthology).
JUNB	transfac_pro__M01216	FOXG1; FOXO1 (directAnnotation).
JUNB	metacluster_161.42	EVX2 (directAnnotation).
JUNB	transfac_pro__M01861	ATF1 (directAnnotation).
JUNB	transfac_pro__M05916	ZNF407 (directAnnotation).
JUNB	cisbp__M00262	ARX (directAnnotation).
JUNB	transfac_pro__M05977	ZNF257 (directAnnotation).
JUNB	metacluster_79.37	FOXJ3 (inferredBy_Orthology).
JUNB	transfac_public__M00415	ZEB1 (directAnnotation).
JUNB	swissregulon__hs__SOX10	SOX10 (directAnnotation).
JUNB	tfdimers__MD00029	IKZF2; NKX3-2 (directAnnotation).
JUNB	transfac_pro__M08883	FOXM1 (directAnnotation).
JUNB	metacluster_188.5	FOXA1; FOXA2; FOXA2; FOXA3; FOXD3; FOXD3; FOXF1; FOXF1; FOXF1; FOXF1; FOXF2; FOXG1; FOXH1; FOXI1; FOXI1; FOXI1; FOXJ1; FOXJ2; FOXL1; FOXO1; FOXO3; FOXO4; FOXO4; FOXQ1 (directAnnotation). FOXK1; FOXL2 (inferredBy_Orthology).
JUNB	transfac_pro__M06794	ZNF107 (directAnnotation).
JUNB	metacluster_41.38	SOX21 (inferredBy_Orthology).
JUNB	transfac_pro__M03888	SOX6 (directAnnotation).
JUNB	transfac_pro__M08882	FOXC2 (directAnnotation).
JUNB	metacluster_161.41	EVX1 (directAnnotation).
JUNB	taipale__IRF7_DBD_RAANCGAAAWTCGNTTY_repr	IRF7 (directAnnotation).
JUNB	transfac_pro__M02015	FOXA3 (directAnnotation).
JUNB	transfac_pro__M01783	SP2 (directAnnotation).
JUNB	swissregulon__mm__Nkx2-3	NKX2-3 (inferredBy_Orthology).
JUNB	taipale_tf_pairs__ELK1_PAX5_RSCGGAACYACGCWYSANTG_CAP_repr	ELK1; PAX5 (directAnnotation).
JUNB	metacluster_167.7	IRF8 (inferredBy_Orthology).
JUNB	transfac_pro__M05349	SNAI3 (directAnnotation).
JUNB	transfac_pro__M05930	ZNF286A (directAnnotation).
JUNB	transfac_pro__M04722	SPI1 (directAnnotation).
JUNB	taipale_tf_pairs__TEAD4_DLX2_RCATTCYNNNCAATTA_CAP	DLX2; TEAD4 (directAnnotation).
JUNB	metacluster_26.4	CDC5L; CDC5L; CDC5L; ZNF580; ZNF580 (directAnnotation).
JUNB	transfac_pro__M04855	IRF4 (directAnnotation).

Page: 1 2 3 4 5 6 7 8

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

TF	motif	Expression	Cell type	Dataset	Timepoint
JUNB	metacluster_137.2	down	Malignant cells	GSE131984_Pac	NA
JUNB	metacluster_111.4	up	CD8+ T cells	GSE152469	NA
JUNB	metacluster_111.4	up	Malignant cells	GSE152469	NA
JUNB	metacluster_111.4	up	B cells	GSE161801_IMiD	pre
JUNB	metacluster_137.2	down	NK cells	GSE161801_IMiD	pre
JUNB	metacluster_157.2	down	NK cells	GSE161801_IMiD	pre
JUNB	metacluster_111.4	up	CD4+ T cells	GSE161801_PI	post
JUNB	metacluster_148.1	up	CD4+ T cells	GSE161801_PI	post
JUNB	metacluster_157.2	up	CD4+ T cells	GSE161801_PI	post
JUNB	metacluster_111.4	up	cDCs	GSE161801_PI	post
JUNB	tfdimers__MD00475	up	CD4+ T cells	GSE161801_PI	pre
JUNB	metacluster_157.2	down	CD8+ T cells	GSE161801_PI	pre
JUNB	metacluster_137.2	down	CD8+ T cells	GSE161801_PI	pre
JUNB	metacluster_50.1	down	CD8+ T cells	GSE161801_PI	pre
JUNB	tfdimers__MD00586	down	Mono/Macro	GSE161801_PI	pre
JUNB	metacluster_157.2	down	cDCs	GSE162117	post
JUNB	metacluster_137.2	down	CD4+ T cells	GSE162117	pre
JUNB	metacluster_157.2	down	CD4+ T cells	GSE162117	pre
JUNB	metacluster_137.5	down	CD4+ T cells	GSE162117	pre
JUNB	tfdimers__MD00165	down	CD8+ T cells	GSE164237	post
JUNB	metacluster_137.2	down	CD8+ T cells	GSE164237	post
JUNB	metacluster_157.2	down	CD8+ T cells	GSE164237	post
JUNB	metacluster_50.1	down	CD8+ T cells	GSE164237	post
JUNB	metacluster_157.2	down	Mono/Macro	GSE164551	NA
JUNB	metacluster_137.2	down	Mono/Macro	GSE164551	NA
JUNB	metacluster_157.2	up	Mono/Macro	GSE169246_PacAteBlood	post
JUNB	tfdimers__MD00141	up	CD8+ T cells	GSE169246_PacAteBlood	pre
JUNB	tfdimers__MD00475	up	CD8+ T cells	GSE169246_PacAteBlood	pre
JUNB	metacluster_50.1	up	CD8+ T cells	GSE169246_PacAteBlood	pre
JUNB	metacluster_137.2	up	CD8+ T cells	GSE169246_PacAteBlood	pre
JUNB	metacluster_157.2	up	CD8+ T cells	GSE169246_PacAteBlood	pre
JUNB	metacluster_157.2	up	cDCs	GSE169246_PacAteBlood	pre
JUNB	metacluster_137.2	up	cDCs	GSE169246_PacAteBlood	pre
JUNB	tfdimers__MD00036	up	CD8+ T cells	GSE169246_PacAteTissue	post
JUNB	metacluster_50.1	up	CD8+ T cells	GSE169246_PacAteTissue	post
JUNB	metacluster_137.2	up	CD8+ T cells	GSE169246_PacAteTissue	post
JUNB	tfdimers__MD00165	down	NK cells	GSE169246_PacAteTissue	pre
JUNB	metacluster_137.2	up	CD8+ T cells	GSE169246_PacBlood	post
JUNB	tfdimers__MD00165	down	Mono/Macro	GSE169246_PacBlood	post
JUNB	metacluster_157.2	down	Mono/Macro	GSE169246_PacBlood	post
JUNB	metacluster_50.1	up	CD4+ T cells	GSE169246_PacTissue	post
JUNB	metacluster_157.2	up	CD4+ T cells	GSE169246_PacTissue	post
JUNB	tfdimers__MD00165	up	CD4+ T cells	GSE169246_PacTissue	post
JUNB	metacluster_157.2	up	CD8+ T cells	GSE169246_PacTissue	post
JUNB	metacluster_137.2	up	NK cells	GSE169246_PacTissue	post
JUNB	metacluster_157.2	up	NK cells	GSE169246_PacTissue	post
JUNB	metacluster_50.1	up	NK cells	GSE169246_PacTissue	post
JUNB	tfdimers__MD00125	up	CD8+ T cells	GSE169246_PacTissue	pre
JUNB	metacluster_111.4	up	CD8+ T cells	GSE169246_PacTissue	pre
JUNB	metacluster_157.2	up	CD8+ T cells	GSE169246_PacTissue	pre

Page: 1 2

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."